Trials / Completed
CompletedNCT04621409
LEAP2 on Postprandial Glucose Metabolism and Food Intake
Effects of LEAP-2 on Postprandial Glucose Metabolism and Food Intake
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University Hospital, Gentofte, Copenhagen · Academic / Other
- Sex
- Male
- Age
- 18 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in healthy volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in healthy subjects.
Detailed description
In a recent study, the molecular phenotype of enteroendocrine cells in the small intestine before and after Roux-en-Y Gastric Bypass (RYGB) surgery in obese individuals was examined. Enteroendocrine cells were identified and isolated from intestinal biopsies and analysed for differentially expressed genes by Illumina High Throughput RNA-sequencing. It was discovered that the gene encoding liver-enriched antimicrobial peptide 2 (LEAP-2), a naturally occurring peptide in humans, was significantly upregulated compared to baseline expression. Interestingly, LEAP-2 was recently shown to antagonize ghrelin function in response to feeding in mice. Moreover, the mature murine LEAP-2 peptide is identical in mice and humans. Thus, LEAP-2 has been identified as an endogenous peptide that may be able to alter feeding behaviour and maintenance of glucose levels during calorie restriction. The study hypothesis is that LEAP-2 alters postprandial glucose metabolism and decreases appetite as well as food intake in relation to a liquid mixed meal and a standardised ad libitum meal compared with saline (placebo) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Liver-enriched antimicrobial peptide 2 | IV infusion of LEAP2, approximately 5 hours |
| BIOLOGICAL | Placebo | IV infusion of saline, approximately 5 hours |
Timeline
- Start date
- 2020-11-17
- Primary completion
- 2021-02-18
- Completion
- 2021-02-18
- First posted
- 2020-11-09
- Last updated
- 2021-05-26
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04621409. Inclusion in this directory is not an endorsement.